Sweden bolsters biotech
Enlarge image

BusinessSweden

Sweden bolsters biotech

05.04.2012 - Swedish pharma company Astra Zeneca plus Wallenberg Foundation and Swedish government pledge a record investment into the biotech industry.

Stockholm – Under a new initiative, AstraZeneca will invest €2.3m to €4.5m (SEK20m to SEK40m) a year over the next five years in early-stage research projects. The Wallenberg Foundation, a private financing institution which is dedicated to promoting scientific research and education in Sweden, will provide additional €25m (SEK220m). The money will be used to build up technology laboratories for the SciLifeLab collaboration between four Swedish universities. The contribution of the Swedish government is yet unknown, but a spokesperson already announced the government is planning a record investment in the country's life science infrastructure. The details would be published in the autumn budget. Jan Björklund, the Swedish Minister for Education, announced the SciLifeLab will become a national research institute for major research in molecular biosciences and bioinformatics. According to the government’s plan, SciLifeLab will grow to employ about 1,000 scientists and have a turnover of about €113m (SEK1bn) within a few years.  SciLifeLab is a joint venture between four universities; Karolinska Institutet, the Royal Institute of Technology, Stockholm University and Uppsala University. The medical research focuses on investigating the molecular basis of complex human diseases, and seeks to find biomarkers that can help diagnose diseases and monitor their progress. The vision is to make SciLifeLab a competitive centre for high-throughput biosciences with platforms in genomics, comparative genetics, proteomics, bioimaging and functional genomics as well as research communities in biology, medicine and environmental sciences.

.

http://www.european-biotechnology-news.com/news/news/2012-02/sweden-bolsters-biotech.html

SurveyGermany

06.05.2015 More revenue, more staff, more funding: in the German biotech industry, all signs are pointing towards growth.

M&ASwitzerland

04.05.2015 Swiss crop chemical maker Syngenta AG is in talks with US company Monsanto to discuss a possible merger, insiders say.

BiofuelsEU

30.04.2015 The European Parliament has given the go-ahead on a new law limiting the use of harmful crop-based biofuel in the transport sector. The decision marks a breakthrough in the EU’s approach to biofuels.

FinancingSwitzerlandUK

29.04.2015 Biopharma start-up CRISPR Therapeutics has raised US$64m to hurry the new CRISPR/Cas9 technology to the clinic.

FinancingBelgium

28.04.2015 After having raised €100m in its stock market debut, MDx company Biocartis has gained 13 percent on its first trading day.

Swiss Biotech DaySwitzerland

16.04.2015 The Swiss biotech industry can look back on 2014 as a good year, but political uncertainties do remain. This was one of the topics discussed during the Swiss Biotech Day in Basel, which attracted more than 400 participants.

FinancingUK

21.04.2015 Ahead of its listing on the London Stock Exchange, Woodford’s Patient Capital Trust has raised a record sum of €1.1bn. The fund met with immense interest by investors.

PoliticsEU

22.04.2015 A legislative proposal by the European Commission is set to renationalise market authorisation of genetically modified crops.

EventEUFrance

16.04.2015 The changing landscape in healthcare was just one of the hotly discussed topics of the 27th Annual EuroMeeting of the international association DIA.

R&DFranceUKSweden

24.04.2015 AstraZeneca has boosted its oncology portfolio by signing a US$1.275bn agreement with Innate Pharma. The companies plan to further the development of Innate’s tumour-targeting antibody.

Events

All Events

Partner-Events

München

BioVaria 2015

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • THERAMETRICS0.08 CHF14.29%
  • 4SC5.75 EUR6.28%
  • WILEX5.43 EUR3.43%

FLOP

  • CYTOS1.17 CHF-7.87%
  • MEDIGENE9.45 EUR-6.99%
  • FORMYCON24.99 EUR-5.02%

TOP

  • 4SC5.75 EUR285.9%
  • WILEX5.43 EUR78.0%
  • SARTORIUS151.95 EUR18.3%

FLOP

  • BIOTEST70.10 EUR-26.1%
  • MEDIGENE9.45 EUR-16.7%
  • CYTOS1.17 CHF-14.6%

TOP

  • SANTHERA93.40 CHF2294.9%
  • CYTOS1.17 CHF735.7%
  • WILEX5.43 EUR531.4%

FLOP

  • MOLOGEN4.79 EUR-56.5%
  • BIOFRONTERA2.39 EUR-26.2%
  • THERAMETRICS0.08 CHF-20.0%

No liability assumed, Date: 06.05.2015